Boryung is a mid-sized, prescription-led Korean pharmaceutical company that crossed KRW 1 trillion in annual revenue for the first time in FY2024 and ranks around eighth among Korean traditional pharma groups by sales. Its franchise rests on three pillars: (1) Kanarb (fimasartan), Korea's most commercially successful home-grown new drug and the base of a family of hypertension and dyslipidaemia combinations; (2) an oncology business built through "Legacy Brands Acquisition" (LBA) — buying and in-sourcing manufacture of off-patent originator brands such as Gemzar, Alimta and, since June 2026, the global Taxotere business acquired from Sanofi; and (3) a cytotoxic and oral-solid manufacturing hub at Yesan Campus that is now being monetised through global CDMO contracts. Under third-generation owner-CEO Jay Kim, the company is reorganising into a manufacturing/R&D/global parent with a separately incorporated commercial subsidiary, while also making long-dated bets on space life sciences through Axiom Space and its BRAX Space joint venture.
---
### What the company does
Boryung manufactures, imports, licenses and sells finished pharmaceuticals, overwhelmingly to the Korean prescription (ETC) market. Its revenue derives from four broad activities:
1. **Self-developed branded drugs** — chiefly the Kanarb family (fimasartan mono and fixed-dose combinations), which represented about 15% of FY2024 revenue (KRW 150.9 billion, iNews24, 2025) and 15.9% of FY2025 revenue (HuffPost Korea, Aug 2026), plus incrementally modified drugs and first-to-file generics (e.g., Lenvanib, a lenvatinib generic approved February 2025).
2. **Acquired originator ("LBA") brands** — Gemzar (gemcitabine, Korean rights from Eli Lilly, 2020), Zyprexa (olanzapine, Korean rights from Lilly, 2021), Alimta (pemetrexed, Korean rights from Lilly, 2022) and Taxotere (docetaxel, global business in 19 countries/regions from Sanofi, closed May/June 2026). Boryung transfers manufacturing of these products in-house to Yesan, improving gross margin (Dealsite, 2025; Daily Pharm, 2025–2026).
3. **In-licensed / co-promoted products ("merchandise")** — e.g., Lilly's Trulicity distribution, HK inno.N's K-CAB co-promotion from 2024 (IBK Securities, Jan/Apr 2024), Organon's Atozet exclusive distribution from August 2026 (Daily Pharm headline, Aug 2026), and biosimilars. The 2023 Daily Pharm interview with then co-CEO Chang Doo-hyun put merchandise at about 40.6% of sales, low by Korean standards.
4. **Contract manufacturing (CDMO) and exports** — Alimta injectable supply to Lotus (Taiwan, contract Dec 2024, first shipment May 2026), Zyprexa tablets to Cheplapharm for up to 46 countries (contract Jul 2025, exports from Q4 2026), Alimta to Zuellig Pharma for seven Southeast Asian markets (contract Oct 2025, supply from 2027), and Taxotere global supply including a seven-year USD 277.1 million contract with China's Yifan Pharmaceutical (Sept 2026).
Consumer/OTC brands historically associated with Boryung — Gelfos (antacid) and Yonggaksan (cough/expectorant) — are manufactured by Boryung, while their OTC marketing and sales are conducted by Boryung Consumer Healthcare, a 100% subsidiary of the parent Boryung Holdings (not of the listed company) since 2018 (Daily Pharm, Apr 2020; Dealsite, Apr 2024). Gelfos holds roughly 30% of the Korean OTC antacid market (Daily Pharm, Jun 2026).
### Business and revenue model
| Revenue type | Description | Share of revenue |
|---|---|---|
| Product sales — own manufactured goods | Kanarb family, in-sourced LBA brands, generics, OTC goods supplied to affiliate | ~59.4% of sales at 3Q22 (Daily Pharm, Feb 2023); later figure not publicly disclosed |
| Merchandise sales — purchased finished goods | In-licensed/co-promoted products (K-CAB, Trulicity, Atozet etc.) | ~40.6% (Daily Pharm, Feb 2023); later figure not publicly disclosed |
| Contract manufacturing / CDMO | Lotus, Cheplapharm, Zuellig; prior domestic contract manufacturing | Not separately disclosed; "Other (export, contract mfg.)" was KRW 75.1bn in FY2023 (IBK Securities) |
| Licensing / royalty | Kanarb out-licensing (Latin America, Russia, China, SE Asia) | Not publicly disclosed (small) |
| Subscription | None | 0% |
### Company's own description
In recruitment and corporate materials, Boryung describes itself as a business that began as Boryung Pharmacy in 1957, entered drug manufacturing in 1963 and grew with Yonggaksan and Gelfos, launched Kanarb in 2011, adopted the LBA strategy in 2020, and passed KRW 1 trillion in sales in 2024, with an ambition to become Korea's leading pharmaceutical company (Remember career postings, 2025–2026). Its mission statement is to become a company indispensable to human health. Its English-language press materials since 2022 have described the group as a "healthcare investment company" (KED Global, Jan 2024; Axiom Space press release, Jan 2024).
### Independent characterisation
Boryung is best understood as a Korean specialty-brand consolidator with captive manufacturing: rather than funding high-risk novel-drug discovery, it buys proven off-patent originator brands, in-sources their production to capture gross margin, and then reuses the resulting regulatory dossiers and EU-GMP capacity to sell manufacturing services and the brands themselves internationally. Kanarb provides a domestic cash engine but is now in post-patent erosion. The space-healthcare programme is a capital-allocation choice by the controlling family rather than an operating business — it has generated no reported revenue (Daily Pharm, Sept 2026).
**Value-chain position:** Formulation, manufacturing (finished dose; not API), regulatory ownership, marketing and distribution. Customers: hospitals (tertiary and secondary), clinics, pharmacies via wholesalers; global pharma partners (CDMO); national distributors abroad (Taxotere). End-markets: cardiovascular/metabolic (hypertension, dyslipidaemia, diabetes), oncology (cytotoxics, targeted generics, supportive care), CNS (Zyprexa ~75.7% of CNS sales in Q1 2026, Dealsite TV, Jun 2026), respiratory/anti-infectives (Mucomyst, Maxipime), gastroenterology.